You are here

Home » Tokyo » Pharmaceuticals

Nippon Boehringer Ingelheim Co. Ltd.

Nippon Boehringer Ingelheim Co. Ltd. is a Japan company, located in Tokyo. more detail is as below.

Company Information

  • Company Name: Nippon Boehringer Ingelheim Co. Ltd.
  • Country: Japan
  • Address: Tokyo
  • International Area Code: 81
  • Phone: 03-6417-2200 (+81-03-6417-2200)
  • Fax: 03-5435-2920 (+81-03-5435-2920)
  • Website:
  • Product List: Pharmaceuticals
  • Category Activities: Pharmaceuticals
  • Type: Manufacturers
  • Profile: Boehringer Ingelheim, A Global Pharmaceutical Corporation With Its Headquarters In Germany, Boasts Tradition Of Sustainable Expansion And Prosperity Since Its Foundation In 1885. The Corporation Now Has More Than 143 Operational Bases In 47 Countries Around The World, And Its Global Sales Of Prescription Medicines Ranks In The Top 20 Worldwide. In Addition To Prescription Medicine Endeavours, The Corporation Is Forging Ahead With Research On Various Diseases And Development Of Consumer Healthcare Products As Well As Drugs For Animal Health. The Corporation Aims To Contribute To The Health And Wellbeing Of People In Many Spheres Of Life By Providing Innovative And Attractive Therapies. In Recent Years, The Corporation Has Become One Of The Leading Forces In The Biopharmaceuticals Field, Due To Its Innovative Technology. Nippon Boehringer Ingelheim, A Japanese Affiliate Of Boehringer Ingelheim, Plays An Important Role In The Operation Of The Corporation, With Prescription Medicine Sales Exceeding Those Of Its Home Country Germany, Ranked Next To The U.s.a. We Committed Ourselves To Acquiring Of Accurate Customer Knowledge And Responding To The “customer’s Viewpoint” And “providing Products And Services That Exceed Customer Expectations,” Which Drives The Company To Pursue Its Activities In The Japanese Market, With The Goal Of Gaining The Trust Of Medical Institutions And Their Patients. Nippon Boehringer Ingelheim Supplies Global Strategic Products And Core Products To Healthcare Professionals And Medical Fields Across Japan. In Addition To Core Products Which Have Enduring And Popular History Of Use (such As “alesion®”, An Antiallergic Agent, And “lendormin®”, A Soporific), The Company Has Recently Developed And Introduced Those Global Strategic Products, Which Are Expected To Become Sales Blockbusters. Those Novel Products Have Been Continuously Introduced Into The Japanese Market Since 2002,, Such As “micardis®” (for The Treatment Of Hypertension), “bi•sifrol®” (an Anti-parkinson’s Disease Drug), And “spiriva®” (for The Treatment Of Chronic Obstructive Pulmonary Disease (copd)). The Company Expects Sales Of These Core Products And Global Strategic Products To Continue Burgeoning And Providing Broader Healthcare Options For Patients In Japan. Boehringer Ingelheim Is An Independent Family-owned Corporation, Hence It Is Not Publicly Traded. Its Corporate Strategy Therefore Has Not Been Negatively Influenced By Short-term Indices Such As Stock Price Fluctuations. Another Significant Benefit Is That The Company Can Implement Its Corporate Mission Based On Mid-term And Long-term Perspectives, In Order To Fulfil Its Social Responsibilities With Foresight And Vision. With Fundamental Advantages Arising From Such Corporate Uniqueness, Nippon Boehringer Ingelheim Takes A Step Ahead By Regarding Its Employees As Valuable “assets”, And Spares Maximum Effort In Nurturing Their Global Perspectives.
  • Area: Tokyo
  • Industry: Pharmaceuticals
More Links

  • Spi Inc.
  • Flash Agent Co. Ltd
  • Nippon Boehringer Ingelheim Co. Ltd.
  • Tokyo Tenbodai
  • Nikko Inc.

    •         ‹ previous | next ›